Schrodinger Inc to Host Pipeline Day Transcript
Good morning, everyone. Welcome to Schrödinger's first pipeline day. I'd like to welcome everyone who's in the room and everyone who's joined the webcast. If you're on the webcast, you may have noticed that we launched our new website this week, which we're really excited about.
During today's presentation, we are, of course, going to make forward-looking statements about our business, and these reflect our views as of today. Actual results may differ materially. And I encourage you to read the risk factors section in our SEC filings, including our most recent SEC filing which was our 10-Q.
Turning to our agenda, we're going to spend some time today doing a deep dive into our pipeline. That includes our MALT1 inhibitor, SGR-1505; our CDC7 inhibitor, 2921; and Wee1/Myt1 inhibitor 3515. We're going to also bookend these scientific presentations with some commentary about the business.
We're excited to have two physicians with us today. We have Dr. Timothy Yap, who's joining us here in the room,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |